MET and renal cell carcinoma: Exosomal lncRNA activated in RCC with sunitinib resistance (lncARSR) was delivered to renal cell carcinoma to promote sunitinib resistance through sponging miR-34/miR-449, which further enhanced AXL and c-MET expression (15).